Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

CaymanStyleBeef May. 19 at 3:14 PM

$ABBV $CELH $NKE $RACE good for a red day...diversified gains...stack um up 🤣

0 · Reply

Blockwave1 May. 19 at 3:14 PM

$ABBV 🩺 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.53 130% GAINER! More wins🔥

0 · Reply

Amscru80 May. 19 at 2:44 PM

$ICCM this is a real gem, news today!! 💎 $SLS $ABBV $PFE $LLY

0 · Reply

Blockwave1 May. 19 at 2:20 PM

$0.37 on $ABBV here! 60% return! 🔥

0 · Reply

Blockwave1 May. 19 at 2:18 PM

ADDED HEAVY!!🚨 $ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE

0 · Reply

Blockwave1 May. 19 at 2:17 PM

$ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE

0 · Reply

Amscru80 May. 19 at 2:03 PM

$ICCM buy now or cry later, with great news!!! 🚀🚀🚀 $SLS $LLY $ABBV $CGON

0 · Reply

Mike22332233 May. 19 at 12:04 PM

$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!

2 · Reply

Mike22332233 May. 19 at 12:36 AM

$SLS SPOT ON — and exactly what many of us have been saying for over a year now !!! … and much of this is what I based my BO final price in a bidding war (between $MRK, $PHE, $ABBV) to be $222 !!!! FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!

0 · Reply

55X_ROI_Q1_2026 May. 18 at 5:57 PM

$SLS -- Is it $PFE $ABBV or $MRK

1 · Reply

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-14T20:15:24.000Z - 4 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

2026-05-14T11:07:12.000Z - 5 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

May 13, 2026, 2:20 PM EDT - 6 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 11 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 13 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 14 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 14 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 15 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 1, 2026, 3:05 PM EDT - 18 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 18 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 19 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 19 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 19 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 19 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 19 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 19 days ago

AbbVie upgraded to Buy from Neutral at BofA

2026-04-29T16:41:09.000Z - 20 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 20 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 20 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T13:25:07.000Z - 20 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

Apr 29, 2026, 9:00 AM EDT - 20 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 20 days ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 20 days ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 20 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 20 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 20 days ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 21 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 21 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 22 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 25 days ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 25 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 27 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 27 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 4 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 5 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 5 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 6 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 6 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 6 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 6 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 6 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 7 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 3 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 3 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 3 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 3 months ago

AbbVie Declares Quarterly Dividend

Feb 13, 2026, 10:00 AM EST - 3 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Annual report: Q4 2025

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings release: Q4 2025

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

CaymanStyleBeef May. 19 at 3:14 PM

$ABBV $CELH $NKE $RACE good for a red day...diversified gains...stack um up 🤣

0 · Reply

Blockwave1 May. 19 at 3:14 PM

$ABBV 🩺 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.53 130% GAINER! More wins🔥

0 · Reply

Amscru80 May. 19 at 2:44 PM

$ICCM this is a real gem, news today!! 💎 $SLS $ABBV $PFE $LLY

0 · Reply

Blockwave1 May. 19 at 2:20 PM

$0.37 on $ABBV here! 60% return! 🔥

0 · Reply

Blockwave1 May. 19 at 2:18 PM

ADDED HEAVY!!🚨 $ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE

0 · Reply

Blockwave1 May. 19 at 2:17 PM

$ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE

0 · Reply

Amscru80 May. 19 at 2:03 PM

$ICCM buy now or cry later, with great news!!! 🚀🚀🚀 $SLS $LLY $ABBV $CGON

0 · Reply

Mike22332233 May. 19 at 12:04 PM

2 · Reply

Mike22332233 May. 19 at 12:36 AM

0 · Reply

55X_ROI_Q1_2026 May. 18 at 5:57 PM

$SLS -- Is it $PFE $ABBV or $MRK

1 · Reply

SellasgpsCurativeBAT12 May. 18 at 4:09 PM

$ABBV $IMGN $LLY $PFE $SLS Volume just crossed 5 million shares in first 2.5 hours of trading. Big Institutional funds gobbling up every loose share before the next PR Hits. ✌️❤️‍🩹🙏

0 · Reply

SellasgpsCurativeBAT12 May. 18 at 3:43 PM

$SLS $ABBV $PFE $MRK AbbVie has already terminated all Viale studies in anticipation of the GPS Regal Pivotal Registrational phase 3 Paradigm shifting data. AbbVie will be the biggest looser if another big pharmaceutical picks up 13 FTE Sellas First. ✌️❤️‍🩹🙏

2 · Reply

SellasgpsCurativeBAT12 May. 18 at 3:36 PM

$IMGN $LLY $PFE $SLS $ABBV AbbVie will make a move before the bidding war starts. I see them coming before the GPS Regal Pivotal Registrational phase 3 data comes out. Ventoclax is $1.9 Billion dollar annual blockbuster for AbbVie. Merck has already done multiple studies with SLS GPS+ Keytruda, with Keytruda patent expiring in 2028. Merck will be part of the bidding war unless AbbVie picks them up pre data read out! ✌️❤️‍🩹🙏

1 · Reply

trenddetector May. 18 at 3:14 PM

$ABBV Blood cancers like leukemia and lymphoma come with a steep learning curve — new terms, new drugs, new decisions, all at once. If someone you know is newly diagnosed and trying to make sense of treatments like Venclexta or Imbruvica, YourCancerPath.com can help them get oriented fast. It's free, anonymous, and built for patients — not doctors. No jargon, no sales pitch, just real guidance. Please share this today with anyone in your life who's in the middle of a cancer fight. They deserve a clearer path. 🔗 YourCancerPath.com #leukemia #lymphoma #ABBV #YourCancerPath

0 · Reply

CapitalMonk May. 18 at 3:09 PM

$ABBV Price: $210.49 (+0.05%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.76% RSI: 67.7 | Momentum: Moderate Volume: -86.5% vs avg Volatility: 1.56% Support: $190.75 | Resistance: $214.92 Sourch: http://marketbaubles.com/

0 · Reply

Mike22332233 May. 18 at 12:11 PM

$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... SLS is the Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...

1 · Reply

Mike22332233 May. 18 at 11:55 AM

$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is twice as long as expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233

1 · Reply

55X_ROI_Q1_2026 May. 17 at 9:10 PM

$SLS IDMC Unblinded actual MOS and IR Data from the Interim Analysis 60th Event - told all industry participants Gps works. Industry Participants: $ABBV $RHHBY Know its not BAT AzaVEN 39 funds invested in SLS, now 160 - the market is telling anyone paying attention.\ the IDMC unblinded Cctual survival data and Immune Response data, at the 60th event, that told market participants who are Familiar and knowledgeable -- 80% Immune Response Rates .. .. is confirmed Efficacy .... MOS survival for all Pooled Patients NYM > 13.5 months for Control + patients on Gps Immunotherapy was 2x longer than Known OS for Control.

0 · Reply

55X_ROI_Q1_2026 May. 17 at 8:05 PM

$SLS SLS Announced the 60th Event, the share price Launched SLS Announced the 72nd Event, the share price Launched SLS Announced the 78th Event, the share price Launched SLS is about to announce the 80th and Final Event ... Not the results just the 80th event, the share Price will launch ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst-Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits don't get conned by the reverse short con....

0 · Reply

UsingAGodAlgorithm May. 16 at 10:54 PM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA

0 · Reply

Mike22332233 May. 16 at 10:51 PM

$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...

4 · Reply

Mike22332233 May. 16 at 9:29 PM

$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is almost twice as long as should be expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233

3 · Reply

Market Cap	371.72B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	20.68
Forward PE	14.72
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	3,219,150
Avg Vol	6,850,402
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	63%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.17